Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
HB1801 Combined Treatment of HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- NA
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Status
- RECRUITING
- Phase
- N/A
A Study of Surgery and Radiotherapy in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
- Status
- RECRUITING
- Phase
- N/A
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
- Status
- RECRUITING
- Phase
- PHASE3
This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
HER2 Vaccine for Locally Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
- Status
- RECRUITING
- Phase
- NA
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
- Status
- RECRUITING
- Phase
- PHASE2